Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products
Adia Med boosts Adia Labs’ biologic inventory to support growing demand from studies, clinics, and partner providers while expanding its research pipeline.
Rhea-AI Summary
Adia Med (ADIA) reports that the estimated retail value of biologic inventory at its Adia Labs division now exceeds $1.5 million, reflecting rising demand and expansion of its clinical studies.
Management estimates that Adia Labs’ biologic inventory had an approximate retail value of $380,000 at the end of Q2 2026, with the increase attributed to higher product demand from clinical studies, commercial sales, and expanded supply to partner providers. Adia Labs supplies AdiaVita, the flagship biologic, to company clinics, outside providers, and four active investigational studies in autism spectrum disorder, chronic kidney disease, lower back pain, and additional research. Adia Med expects to launch five more studies later in 2026. As of June 30, 2026, biologic inventory was reported at a U.S. GAAP carrying cost of $140,500, and all products and studies remain investigational and not FDA-approved to diagnose, treat, cure, or prevent disease.
Positive
- Estimated biologic inventory retail value now exceeds $1.5 million
- Retail value rose from about $380,000 at Q2 2026 end
- Four active investigational studies, with five additional studies expected in 2026
- Chronic kidney disease and lower back pain trials start treating participants on October 1
Negative
- Biologic inventory carrying cost under U.S. GAAP was only $140,500 at June 30, 2026
- All clinical studies are investigational and participation does not guarantee outcomes
- Adia Med products are not FDA-approved to diagnose, treat, cure, or prevent any disease
AI-generated analysis. How Rhea-AI works. Not financial advice.
Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds
Management estimates that Adia Labs' biologic inventory had a retail value of approximately
"Demand is coming from product sales and from our studies at the same time," said Larry Powalisz, Chief Executive Officer of Adia Med Inc. "Building inventory at Adia Labs is a practical step so we can support current patients, partner clinics, and the additional studies we expect to launch in 2026."
Adia Labs supplies AdiaVita, the Company's flagship product, to Adia Med clinics, outside providers, and the Company's four active studies. The active research programs include IRB-approved studies in autism spectrum disorder, chronic kidney disease, and lower back pain, along with additional research already underway. Adia Med also expects to launch five additional studies later this year, including protocols in planning or IRB review.
The Company's lead Autism Spectrum Disorder study (NCT07304440) continues enrollment after completion of Phase 1 treatment for its first cohort. The Chronic Kidney Disease study (NCT07572890) and Lower Back Pain study (NCT07587047) remain listed as recruiting on ClinicalTrials.gov and start treating participants October 1st.
Retail value is a management estimate of selling price and is not the same as inventory value reported under U.S. GAAP in the Company's SEC filings. At June 30, 2026, biologic inventory was reported at a carrying cost of
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.
About Adia Med Inc.
Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies, The current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products, including its flagship product AdiaVita, and AdiaLink, that supply this clinical work.
Adia Labs generates revenue by manufacturing and selling regenerative products (AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments (stem cell therapies, PRP, TPE, and aHSCT). Additional revenue comes from the company's
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/315356
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is AdiaVita and who receives it?
AdiaVita is Adia Med’s flagship biologic product. Adia Labs supplies AdiaVita to Adia Med clinics, outside providers, and the company’s four active investigational studies.
Which conditions are Adia Med’s current clinical studies targeting?
The active research programs include IRB-approved studies in autism spectrum disorder, chronic kidney disease, and lower back pain, as well as additional research already underway.
What is the status of Adia Med’s lead Autism Spectrum Disorder study?
The lead Autism Spectrum Disorder study (NCT07304440) continues enrollment following completion of Phase 1 treatment for its first cohort.
When do the chronic kidney disease and lower back pain trials begin treating participants?
The Chronic Kidney Disease study (NCT07572890) and Lower Back Pain study (NCT07587047) are listed as recruiting on ClinicalTrials.gov and are scheduled to start treating participants on October 1.
How does Adia Med define the retail value of biologic inventory?
Retail value is described as a management estimate of selling price and is not the same as the inventory value reported under U.S. GAAP in the company’s SEC filings.
How can interested parties contact Adia Med for more information?
Questions and inquiries can be directed to CEO Larry Powalisz via email at ceo@adiamed.com or by phone at 321-231-2843.